Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PWSL | ISIN: US74365A3095 | Ticker-Symbol: PBDA
Tradegate
30.06.25 | 19:18
1,270 Euro
+1,60 % +0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PROTALIX BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTALIX BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2501,27030.06.
1,2201,28030.06.

Aktuelle News zur PROTALIX BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoProtalix BioTherapeutics, Inc. - 8-K, Current Report3
09.05.Protalix BioTherapeutics targets phase 2 launch for PRX-115 in H2 202512
09.05.Protalix BioTherapeutics Inc. Q1 Loss Narrows449JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares...
► Artikel lesen
09.05.Protalix BioTherapeutics GAAP EPS of -$0.05 misses by $0.13, revenue of $10.11M misses by $11.49M6
09.05.Protalix BioTherapeutics, Inc. - 10-Q, Quarterly Report9
PROTALIX BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
09.05.Protalix BioTherapeutics, Inc. - 8-K, Current Report11
09.05.Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results532Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:...
► Artikel lesen
08.05.Uncovering Potential: Protalix BioTherapeutics' Earnings Preview14
08.05.Protalix BioTherapeutics Q1 Earnings Preview2
23.04.Protalix BioTherapeutics, Inc. - 8-K, Current Report7
17.03.Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond13
17.03.Amended: Protalix Annual Earnings Fall466JERUSALEM (dpa-AFX) - (Amended: Recasting the story to correct the period, revenue)Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday reported a decline in earnings for...
► Artikel lesen
17.03.Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 20305
17.03.Protalix Q4 Earnings Fall, Stock Up In Pre-market299JERUSALEM (dpa-AFX) - Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday announced that net income declined in the fourth quarter compared with last year. Shares of Protalix...
► Artikel lesen
17.03.Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results1.253Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:...
► Artikel lesen
17.03.Protalix BioTherapeutics, Inc. - 10-K, Annual Report4
17.03.Protalix BioTherapeutics Inc. Reveals Fall In Full Year Bottom Line321JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) announced earnings for full year that decreased from the same period last yearThe company's earnings totaled $2.93 million, or $0.04...
► Artikel lesen
17.03.Protalix BioTherapeutics GAAP EPS of $0.04, revenue of $53.4M2
17.03.Protalix BioTherapeutics, Inc. - 8-K, Current Report2
14.03.Protalix BioTherapeutics Q4 Earnings Preview5
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1